GeoVax Labs, Inc. announced the appointment of Arban Domi, Ph.D., as its Director, Vector Development. Dr. Domi will not only be a key player in the continued development of GeoVax's HIV vaccines currently being evaluated in human clinical trials, but also in the development of versions of the Company's vaccines for the subtypes of HIV affecting the developing world. Dr. Domi's experience will also be instrumental in the company's evaluation of the suitability of vaccine constructs for commercial-scale vaccine manufacturing processes.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.74 USD | +2.96% | +2.35% | -67.87% |
05-14 | Transcript : GeoVax Labs, Inc., Q1 2024 Earnings Call, May 14, 2024 | |
03-28 | GeoVax Labs, Inc. to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-67.87% | 4.4M | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+44.53% | 40.65B | |
-10.72% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- GOVX Stock
- News GeoVax Labs, Inc.
- GeoVax Labs, Inc. Appoints Arban Domi as Director, Vector Development